Apimeds Pharmaceuticals US: 2-year master service agreement with BlockAssure

What happened

• MindWave Innovations Inc., a wholly owned subsidiary of Apimeds Pharmaceuticals US, Inc., issued a press release on Oct 4, 2026 announcing that it had entered into a 2-year Master Service Agreement with BlockAssure Inc.
• Under the agreement, MindWave will build, deploy, operate and maintain AssureChain, a dedicated subnet of MindChain for recording and executing BlockAssure’s insurance contracts, reinsurance treaties, insurance policies and claims processes on-chain.
• The agreement renews automatically for successive 1-year periods unless either party gives notice of non-renewal.

Key details

• Consideration includes a fixed development fee payable in quarterly installments, operate and maintenance fees to be agreed, and an allocation to MindWave of AssureCoin equal to 20% of its total supply.
• The announcement was made via a press release attached to the filing.
• The filing includes forward-looking statements and notes risks such as development timelines, technical performance, token creation and value, and regulatory requirements.

Why it may matter

• This disclosure was reported under Item 8.01 (Other events), which covers the MindWave press release announcing the Master Service Agreement with BlockAssure.
• The filing does not show why the company acted.